Standard BioTools Inc. (LAB) Ownership
LAB ownership summary
as of October 17, 2026- Institutions
- 75.7% of shares outstanding
- Insiders
- 1.84% of shares outstanding
- Shares outstanding
- 392.6M
- Float
- 184.6M shares available to trade
- Short interest
- 1.06% 2.5M shares short
- Days to cover
- 1.83 short interest down 2.8% vs prior month
- Institutions 75.72%
- Insiders 1.84%
- Other investors 22.44%
LAB top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Casdin Capital, LLC | 22.62% | 88.8M | $55.9M | — | June 30, 2026 |
| 2 | Viking Global Investors LP | 14.94% | 58.7M | $37.0M | — | June 30, 2026 |
| 3 | Mak Capital One LLC | 7.34% | 28.8M | $18.2M | +2.6M (+10.1%) | June 30, 2026 |
| 4 | Long Focus Capital Management, LLC | 5.99% | 23.5M | $14.8M | +7.5M (+46.7%) | June 30, 2026 |
| 5 | Vanguard Capital Management, LLC | 3.12% | 12.3M | $7.7M | −563,072 (−4.4%) | June 30, 2026 |
| 6 | BlackRock Inc | 2.10% | 8.3M | $5.2M | −16.5M (−66.7%) | June 30, 2026 |
| 7 | Hollow Brook Wealth Management, LLC | 1.40% | 5.5M | $3.5M | −150,000 (−2.7%) | June 30, 2026 |
| 8 | Neuberger Berman Group LLC | 1.26% | 5.0M | $3.1M | +301,035 (+6.5%) | June 30, 2026 |
| 9 | Qube Research & Technologies | 1.23% | 4.8M | $3.0M | +4.1M (+584.3%) | June 30, 2026 |
| 10 | Royce & Associates, LP | 1.15% | 4.5M | $2.9M | +1.5M (+50.6%) | June 30, 2026 |
| 11 | Geode Capital Management, LLC | 0.99% | 3.9M | $2.5M | −3.4M (−46.5%) | June 30, 2026 |
| 12 | Tikvah Management LLC | 0.90% | 3.6M | $2.2M | −94 (−0.0%) | June 30, 2026 |
| 13 | Millennium Management LLC | 0.89% | 3.5M | $2.2M | +1.4M (+67.1%) | June 30, 2026 |
| 14 | Morgan Stanley - Brokerage Accounts | 0.72% | 2.8M | $1.8M | −55,478 (−1.9%) | June 30, 2026 |
| 15 | D. E. Shaw & Co LP | 0.72% | 2.8M | $1.8M | +2.6M (+1,315.5%) | June 30, 2026 |
| 16 | Jane Street Group LLC | 0.64% | 2.5M | $1.6M | +2.5M (0.0%) | June 30, 2026 |
| 17 | Peapod Lane Capital LLC | 0.61% | 2.4M | $1.5M | +382,947 (+18.9%) | June 30, 2026 |
| 18 | Citadel Advisors Llc | 0.60% | 2.3M | $1.5M | +1.1M (+91.7%) | June 30, 2026 |
| 19 | Mink Brook Asset Management LLC | 0.56% | 2.2M | $1.4M | +2.2M (0.0%) | June 30, 2026 |
| 20 | Sone Capital Management | 0.54% | 2.1M | $1.3M | +366,850 (+20.8%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 12 holders added 26.7M shares and 6 cut 20.7M.
LAB top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.21% | 8.7M | $5.5M | — | August 31, 2026 |
| 2 | iShares Biotechnology ETF | 0.75% | 2.9M | $1.8M | −22,168 (−0.8%) | September 30, 2026 |
| 3 | Royce Micro-Cap Trust | 0.73% | 2.9M | $1.8M | +1.0M (+53.8%) | June 30, 2026 |
| 4 | Schwab US Small-Cap ETF™ | 0.38% | 1.5M | $927,684 | +990 (+0.1%) | September 30, 2026 |
| 5 | Fidelity Extended Market Index | 0.35% | 1.4M | $867,628 | −184,014 (−11.8%) | August 31, 2026 |
| 6 | Royce Micro-Cap Invmt | 0.32% | 1.2M | $786,182 | +384,612 (+44.6%) | June 30, 2026 |
| 7 | Neuberger Intrinsic Value I | 0.26% | 1.0M | $652,897 | — | August 31, 2026 |
| 8 | Vanguard Health Care ETF | 0.17% | 683K | $430,230 | +2,976 (+0.4%) | August 31, 2026 |
| 9 | Morgan Stanley Inst Inception I | 0.17% | 655K | $412,566 | — | June 30, 2026 |
| 10 | Fidelity Total Market Index | 0.14% | 558K | $351,448 | +11,895 (+2.2%) | August 31, 2026 |
| 11 | EQ/Morgan Stanley Small Cap Growth K | 0.13% | 504K | $317,211 | — | August 31, 2026 |
| 12 | iShares Healthcare Innov ETF USD Acc | 0.13% | 501K | $315,893 | +1,884 (+0.4%) | September 30, 2026 |
| 13 | Neuberger US Sm Cp Intrs Val USD I Acc | 0.12% | 480K | $302,372 | +37,592 (+8.5%) | June 30, 2026 |
| 14 | Fidelity Series Total Market Index | 0.12% | 474K | $298,496 | +13,588 (+3.0%) | August 31, 2026 |
| 15 | Royce Capital Micro-Cap Inv | 0.10% | 406K | $256,014 | +131,268 (+47.7%) | June 30, 2026 |
| 16 | iShares Core S&P Total US Stock Mkt ETF | 0.09% | 337K | $212,067 | +290 (+0.1%) | September 30, 2026 |
| 17 | Column Small Cap Select | 0.08% | 305K | $192,309 | +865 (+0.3%) | June 30, 2026 |
| 18 | Global X Genomics & Biotech ETF USD Acc | 0.08% | 299K | $188,250 | +2,168 (+0.7%) | September 30, 2026 |
| 19 | Global X Genomics & Biotechnology ETF | 0.06% | 224K | $140,971 | — | September 30, 2026 |
| 20 | Invesco NASDAQ Future Gen 200 ETF | 0.05% | 182K | $114,702 | — | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
LAB insider transactions
latest 20| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-04 | Casdin Partners Master Fund, L | Buy | $1.45 | 150,000 | $217,500 |
| 2025-12-03 | Casdin Partners Master Fund, L | Buy | $1.44 | 75,000 | $108,000 |
| 2025-12-02 | Casdin Partners Master Fund, L | Buy | $1.42 | 125,000 | $177,500 |
| 2025-11-25 | Casdin Partners Master Fund, L | Buy | $1.30 | 7,550,000 | $9.8M |
| 2025-11-24 | Casdin Partners Master Fund, L | Buy | $1.43 | 150,000 | $214,500 |
| 2025-11-20 | Casdin Partners Master Fund, L | Buy | $1.30 | 450,000 | $585,000 |
| 2025-11-19 | Casdin Partners Master Fund, L | Buy | $1.28 | 350,000 | $448,000 |
| 2025-11-18 | Casdin Partners Master Fund, L | Buy | $1.23 | 275,000 | $338,250 |
| 2025-11-17 | Casdin Partners Master Fund, L | Buy | $1.22 | 225,000 | $274,500 |
| 2025-11-14 | Casdin Partners Master Fund, L | Buy | $1.24 | 250,000 | $310,000 |
| 2025-11-13 | Casdin Partners Master Fund, L | Buy | $1.20 | 450,000 | $540,000 |
| 2025-11-12 | Casdin Partners Master Fund, L | Buy | $1.19 | 375,000 | $446,250 |
| 2025-11-11 | Casdin Partners Master Fund, L | Buy | $1.20 | 300,000 | $360,000 |
| 2025-11-10 | Casdin Partners Master Fund, L | Buy | $1.17 | 275,000 | $321,750 |
| 2025-11-07 | Casdin Partners Master Fund, L | Buy | $1.12 | 225,000 | $252,000 |
| 2025-09-09 | Casdin Partners Master Fund, L | Buy | $1.29 | 100,000 | $129,000 |
| 2025-09-03 | Casdin Partners Master Fund, L | Buy | $1.27 | 250,000 | $317,500 |
| 2025-08-26 | Casdin Partners Master Fund, L | Buy | $1.26 | 125,000 | $157,500 |
| 2025-08-25 | Casdin Partners Master Fund, L | Buy | $1.24 | 200,000 | $248,000 |
| 2025-08-22 | Casdin Partners Master Fund, L | Buy | $1.26 | 200,000 | $252,000 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
LAB shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns LAB
Institutional investors own 75.7% of Standard BioTools's shares and insiders 1.84%. The largest holder is Casdin Capital, LLC with 22.62% of the shares (88.8M), as of June 30, 2026. Among the top 20 institutions, 12 added shares and 6 reduced their stake in the latest filings. Short interest is 1.06% of the float, or 1.83 days of average trading volume. The share count rose 1,264.1% since 2014.
Related: LAB analyst forecast, LAB key metrics. See the LAB stock overview for the latest quote and news.
LAB ownership FAQ
Who owns the most Standard BioTools stock?
The largest shareholders of Standard BioTools are Casdin Capital, LLC (22.62%), Viking Global Investors LP (14.94%), Mak Capital One LLC (7.34%), Long Focus Capital Management, LLC (5.99%), Vanguard Capital Management, LLC (3.12%).
What percentage of Standard BioTools is owned by institutions?
Institutions hold 75.7% of Standard BioTools's shares outstanding; insiders hold 1.84%.
Which funds own Standard BioTools?
The largest fund holders of Standard BioTools are Vanguard MStar Total Stk Mkt Idx Invest (2.21%), iShares Biotechnology ETF (0.75%), Royce Micro-Cap Trust (0.73%), Schwab US Small-Cap ETF™ (0.38%), Fidelity Extended Market Index (0.35%).
What is Standard BioTools's short interest?
2.5M shares of Standard BioTools were sold short, 1.06% of the float; at the average daily volume it would take 1.83 days to cover.
Are insiders buying or selling Standard BioTools?
Of the latest 20 reported insider transactions in Standard BioTools (since August 22, 2025), 20 were purchases and 0 were sales.
How many shares of Standard BioTools are outstanding?
Standard BioTools has 392.6M shares outstanding, of which 184.6M are in the public float.